Lung cancer staging

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 4, 2002, Pages 287-293

  Barker, John M ^a   Silvestri, Gerard A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER;

CANCER STAGING; ENDOSCOPIC ECHOGRAPHY; HUMAN; LUNG CANCER; METASTASIS; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW;

EID: 0036280344     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200207000-00008     Document Type: Review

References (86)

1. Cancer statistics, 2001
2. A new international system for staging lung cancer
3. Revisions in the international system for staging lung cancer
4. Computed tomography for preoperative assessment of T3 and T4 bronchogenic carcinoma
5. Interobserver variability and accuracy of computed tomographic assessment of nodal status
6. The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer
7. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging
8. Comparison of imaging TNM [(i)TNM] and pathological TNM [ptnm] in staging of bronchogenic carcinoma
9. Lung cancer staging and management: Comparison of contrast-enhaced and nonenhanced helical CT of the thorax
10. Variability in the detection of enlarged mediastinal lymph nodes in staging lung cancer: A comparison of contrast-enhanced and unenhanced CT
11. Transthoracic needle biopsy of mediastinal lymph nodes for staging lung and other cancers
12. Percutaneous core needle biopsy in the diagnosis of mediastinal tumors
13. Percutaneous transthoracic fine-needle lung biopsy with 3 different needles
14. The role of transcarinal needle aspiration in the staging of bronchogenic carcinoma
15. Comparison of the Wang 19-gauge and 22-gauge needles in the mediastinal staging of lung cancer
16. Transcarinal needle aspiration biopsy in the staging of lung cancer
17. Cytologic versus histologic evaluation of needle biopsy of the lung, hilum, and mediastinum: Sensitivity, specificity and typing accuracy
18. Transbronchial fine needle aspiration in clinical practice
19. Immediate on-site interpretation of fine-needle aspiration smears: A cost and compensation analysis
20. CT scan directed transbronchial needle aspiration biopsy for mediastinal nodes
21. CT fluoroscopy guidance for transbronchial needle aspiration. An experience in 35 patients
22. Endobronchial ultrasound-guided needle aspiration of mediastinal adenopathy
23. Diagnostic value of endoscopic ultrasonography-guided fine-needle aspiration cytology of mediastinal masses in patients with intrapulmonary lesions and nondiagnostic bronchoscopy
24. Mediastinoscopy as a routine outpatient procedure
25. Extended cervical mediastinoscopy: Prospective study of fifty cases
26. Mediastinal staging of non-small-cell lung cancer: Computed tomography and cervical mediastinoscopy
27. The value of cervical mediastinoscopy combinded with anterior mediastinotomy in the preoperative evaluation of bronchogenic carcinoma of the left upper lobe
28. Clinical value of cervical mediastinoscopy in the staging of bronchial carcinoma
29. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer
30. Is there a role for routine mediastinoscopy in patients with peripheral T1 lung cancers?
31. Extended cervical mediastinoscopy in the staging of bronchogenic carcinoma
32. Mediastinal staging of lung cancer: Is mediastinoscopy still essential?
33. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
34. Endoscopic ultrasonography of the mediastinum in the diagnosis of bronchial carcinoma
35. Non-small-cell lung cancer: Detection of mediastinal lymph node metastases by endoscopic ultrasound and CT
36. Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of lung cancer
37. Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography, and computed tomography in the preoperative staging of non-small-cell lung cancer: A comparison study
38. An early comparison between endoscopic ultrasound-guided fine-needle aspiration and mediastinoscopy for diagnosis of mediastinal malignancy
39. Role of transesophageal endosconography-guided fine-needle aspiration in the diagnosis of lung cancer
40. Evaluation of mediastinal lymphadenopathy with endoscopic US-guided fine-needle aspiration biopsy
41. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung
42. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
43. Comparative efficacy of positron emission tomography with Glucodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions
44. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases
45. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases?
46. Selective use of PET scan in the preoperative staging of NSCLC
47. Improvement of non-small-cell lung cancer staging by means of positron emission tomography
48. Evaluation of fluorine-18-fluorodeoxyglucose whole body poitron emission tomography imaging in the staging of lung cancer
49. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer
50. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease
51. Factors associated with false-positive staging of lung cancer by positron emission tomography
52. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer
53. How useful is positron emission tomography for lymph node staging in non-small-cell lung cancer?
54. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients
55. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease
56. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy
57. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma
58. Meta-analysis of the efficacy of positron emission tomography with F-18-flueorodeocyglucose in lung tumors
59. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment
60. Mediastinal lymph node sampling following position emission tomography with glucodeoxyglucose imaging in lung cancer staging
61. Early experience with PET scanning in thoracic tumours
62. Staging and managing lung tumors using F-18 FDG coincidence detection
63. Positron emission tomography in the staging of small-cell lung cancer: A preliminary study
64. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer
65. Mediastinal lymph node metastasis from lung cancer: Evaluation with TI-201 SPECT - Comparison with CT
66. Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs
67. "Silent" brain metastasis from lung carcinoma determined by computerized tomography
68. The value of routine cranial computed tomography in neurologically intact patients with primary carcinoma of the lung
69. Clinical/non-invasive staging
70. The clinical evaluation for detecting metastatic lung cancer: A meta-analysis
71. Detection of brain metastasis in potentially operable non-small lung cancer: A comparison of CT and MRI
72. Initial staging of non-small cell lung cancer: Value of routine radioisotope bone scanning
73. Detection of extrathoracic metastases by positron emission tomography in lung cancer
74. The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer
75. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer
76. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: Correlation with platelet and leukocyte counts
77. Plasmja VEGF concentration can predict the tumor angiogenic capcity in non-small cell lung cancer
78. Serum anti-p53 antibodies in lung cancer: Comparison with establish tumor markers
79. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: A Cancer and Leukemia Group B study
80. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival
81. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas